Pricing & Market Dynamics

Drug pricing in Canada is shaped by a complex, globally influenced system that balances affordability with a sustainable pharmaceutical supply. At its centre, the Patented Medicine Prices Review Board (PMPRB) ensures patented medicine prices are not excessive while monitoring broader pricing trends.

Balancing Affordability, Access, and Sustainability

Drug pricing in Canada is not determined by a single factor—it is the result of a complex, globally influenced system that balances affordability for patients with the need to sustain a . At the centre of this system is the Patented Medicine Prices Review Board (PMPRB), a federal body that ensures prices are not excessive while monitoring broader pricing trends.

Drug pricing is more than a regulatory issue

It is a core supply chain consideration that directly impacts access, availability, and long-term system resilience.

Canada in a Global Pricing Environment

Pharmaceutical pricing operates within a global marketplace, where manufacturers set prices across multiple countries based on market size, regulation, and reimbursement systems.

Canada’s approach is unique:

  • Prices are reviewed, not set, by regulators 
  • Benchmarking often considers international price comparisons 
  • Pricing must align with both clinical value and existing therapies 

This positions Canada as a mid-sized, highly regulated market, dependent on global pricing strategies but focused on domestic affordability.

The Role of the PMPRB

The PMPRB plays a critical role in maintaining balance within the system by preventing excessive pricing of patented medicines; monitoring market trends, including pricing, utilization, and R&D investment; and supporting evidence-based decision-making for payers and policymakers.

Importantly, the PMPRB does not directly set prices. Instead, it establishes thresholds and conducts reviews, intervening when prices exceed acceptable limits. 

Recent reforms, including updated Guidelines effective in 2026, introduce a more structured review process that compares prices across countries and similar treatments. 

Why Drug Pricing Matters to the Supply Chain

Drug pricing is often viewed through an affordability lens, but it also has direct implications for supply chain performance and the physical access of medicines.

Drug pricing plays a direct role in sustaining the pharmaceutical supply chain itself. Distribution is supported through the overall pricing and reimbursement framework for medicines. When pricing structures do not adequately reflect the cost and complexity of moving medicines across Canada, it can place pressure on supply chain operations—affecting service levels, investment, and long-term resilience.

Market Attractiveness and Supply Availability

  • Pricing levels influence whether manufacturers prioritize Canada for product launches and supply allocation.
  • Lower prices relative to other markets can affect inventory levels, allocation decisions, and risk of shortages.

Global Flow of Medicines and System Sustainability

  • Because medicines move across borders, pricing disparities can create cross-market pressures, including parallel trade or importation risks and shifts in supply toward higher-priced markets.
  • A well-functioning pricing framework helps ensure long-term access to innovative therapies, predictable supply chain operations, and balanced healthcare spending .

A System Designed for Balance

Canada’s pharmaceutical pricing system is designed to achieve three core outcomes:

  1. Protect Patients: Ensure medicines remain affordable and accessible 
  2. Support Sustainability: Enable stable, predictable supply across the country 
  3. Align with Global Markets: Reflect international pricing realities without overexposing domestic supply 

The PMPRB contributes to this balance by acting as a check on pricing while providing transparency into market trends. 

Vital’s Perspective

At Vital, we view drug pricing as a critical lever within the broader pharmaceutical supply chain.

We support policies that:

  • Maintain fair and predictable pricing frameworks 
  • Recognize the global nature of pharmaceutical supply 
  • Protect Canada’s ability to secure consistent and reliable access to medicines 

Drug pricing decisions must consider not only cost, but also their downstream impact on supply, availability, and patient outcomes.

Looking Ahead

As Canada continues to evolve its pricing framework, including the implementation of updated PMPRB Guidelines, the focus must remain on balance.

Future policy decisions should reflect global supply chain realities, support timely access to new medicines, and ensure Canada remains a viable and stable market within the global pharmaceutical ecosystem.

Vital will continue to advocate for pricing policies that strengthen, not strain, Canada’s pharmaceutical supply chain.

Formal submissions

Advocacy

Learn more